Profile data is unavailable for this security.
About the company
Sumitomo Pharma Co Ltd, formerly Sumitomo Dainippon Pharma Co Ltd, is a Japan-based pharmaceutical company. The Company operates its business through four segments. The Japan segment is engaged in the manufacture, purchase, and sale of ethical drugs. The North American segment is engaged in the manufacture, purchase, and sale of ethical drugs and conducts research and development in the areas of oncology, urology, respiratory disease, and regenerative cell medicine. The China segment is engaged in the manufacture (small packaged products) and sale of ethical pharmaceuticals. The Overseas Others segment is engaged in the manufacture and sale of ethical pharmaceuticals in Europe. The segment also purchase and sell ethical pharmaceuticals in Southeast Asia and Taiwan, as well as provide information and collection activities for the Company's products. Other business includes manufacturing, purchasing, and sales of food ingredients, food additives and chemical product materials.
- Revenue in JPY (TTM)342.67bn
- Net income in JPY-279.46bn
- Incorporated1897
- Employees4.98k
- LocationSumitomo Pharma Co Ltd2-6-8, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
- Phone+81 662035321
- Fax+81 662026028
- Websitehttps://www.sumitomo-pharma.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zeria Pharmaceutical Co Ltd | 78.88bn | 9.03bn | 117.77bn | 1.78k | 10.82 | 1.19 | 7.02 | 1.49 | 204.82 | 204.82 | 1,789.40 | 1,858.72 | 0.5418 | 1.50 | 3.71 | 44,387,400.00 | 6.20 | 3.89 | 9.82 | 6.28 | 73.22 | 71.93 | 11.44 | 7.57 | 0.8393 | -- | 0.3508 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
| Torii Pharmaceutical Co Ltd | 58.84bn | 5.28bn | 122.40bn | 583.00 | 22.64 | 0.9949 | 21.48 | 2.08 | 187.71 | 187.71 | 2,093.33 | 4,271.84 | 0.4411 | 2.74 | 2.30 | 100,924,500.00 | 3.96 | 6.52 | 4.39 | 7.35 | 44.46 | 49.55 | 8.97 | 17.98 | 5.19 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
| Mochida Pharmaceutical Co Ltd | 104.51bn | 4.53bn | 125.15bn | 1.52k | 26.14 | 0.9171 | 16.84 | 1.20 | 127.75 | 127.75 | 2,945.16 | 3,641.81 | 0.6639 | 1.80 | 3.42 | 68,662,940.00 | 2.88 | 4.37 | 3.41 | 5.31 | 49.61 | 52.47 | 4.34 | 6.71 | 3.50 | -- | -- | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
| Towa Pharmaceutical Co Ltd | 235.95bn | 16.92bn | 161.76bn | 4.59k | 9.14 | 0.9482 | 4.59 | 0.6856 | 343.72 | 343.72 | 4,793.82 | 3,311.49 | 0.5582 | 1.49 | 3.60 | 51,428,070.00 | 4.00 | 4.21 | 4.91 | 5.63 | 35.90 | 39.23 | 7.17 | 7.23 | 1.62 | -- | 0.5666 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
| KAKEN PHARMACEUTICAL CO., LTD. | 87.25bn | 18.24bn | 177.74bn | 1.14k | 8.03 | 0.949 | 8.51 | 2.04 | 481.71 | 481.71 | 2,303.80 | 4,076.80 | 0.4864 | 1.98 | 3.88 | 76,867,840.00 | 10.17 | 6.83 | 11.66 | 7.87 | 60.66 | 54.78 | 20.91 | 14.48 | 4.47 | -- | 0.0243 | 51.25 | -1.29 | -5.21 | 47.52 | -14.70 | 0.3639 | 0.00 |
| Kissei Pharmaceutical Co Ltd | 81.07bn | 10.73bn | 180.48bn | 1.78k | 15.14 | 0.7366 | 11.82 | 2.23 | 241.71 | 241.71 | 1,825.83 | 4,969.03 | 0.3294 | 1.60 | 2.98 | 45,568,860.00 | 4.38 | 3.61 | 4.75 | 3.90 | 49.88 | 49.47 | 13.31 | 12.69 | 4.15 | -- | 0.0057 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
| Sumitomo Pharma Co Ltd | 342.67bn | -279.46bn | 233.57bn | 4.98k | -- | 2.04 | -- | 0.6816 | -703.41 | -703.41 | 862.50 | 287.37 | 0.3517 | 1.30 | 4.28 | 68,808,230.00 | -28.68 | -5.07 | -51.21 | -7.73 | 59.56 | 69.99 | -81.54 | -12.28 | 0.424 | -12.10 | 0.7732 | -- | -43.38 | -7.29 | -322.71 | -- | 4.02 | -- |
| Sawai Group Holdings Co Ltd | 178.04bn | 17.78bn | 259.19bn | 3.48k | 14.61 | 1.21 | 8.58 | 1.46 | 134.98 | 194.99 | 1,352.92 | 1,627.68 | 0.4671 | 1.17 | 2.83 | 51,130,670.00 | 3.48 | 0.7104 | 4.62 | 0.9705 | 31.14 | 35.08 | 7.44 | 1.47 | 1.58 | 43.19 | 0.2927 | 88.13 | 8.04 | -0.8249 | 46.82 | -2.33 | 18.15 | 0.00 |
| Nippon Shinyaku Co., Ltd. | 150.37bn | 27.37bn | 287.89bn | 2.21k | 10.09 | 1.22 | 8.83 | 1.91 | 406.30 | 406.30 | 2,232.62 | 3,372.50 | 0.5976 | 1.37 | 3.20 | 67,949,390.00 | 10.88 | 10.45 | 12.41 | 12.31 | 66.81 | 61.27 | 18.20 | 16.47 | 3.73 | -- | 0.0114 | 32.62 | 2.83 | 5.26 | 13.32 | 9.66 | 45.93 | 12.12 |
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 03 Oct 2024 | 13.77m | 3.46% |
| Nikko Asset Management Co., Ltd.as of 04 Oct 2024 | 6.89m | 1.73% |
| Daiwa Asset Management Co. Ltd.as of 30 Sep 2024 | 6.46m | 1.62% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 5.84m | 1.47% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 03 Oct 2024 | 3.35m | 0.84% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.88m | 0.73% |
| Arcus Investment Ltd.as of 31 Mar 2024 | 2.84m | 0.71% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 2.11m | 0.53% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 2.11m | 0.53% |
| BlackRock Japan Co. Ltd.as of 03 Oct 2024 | 1.55m | 0.39% |
